The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
|
4 min read
A new law that allows patients with rare diseases to participate in clinical trials without losing eligibility for public health care benefits went into effect yesterday. The bill, known as the “Improving Access to Clinical Trials Act” (IACT), was championed by the Cystic Fibrosis Foundation and signed into law in October 2010.
|
2 min read
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
|
4 min read
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
|
2 min read
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
|
3 min read
Legislation Would Remove Financial Penalties for Participating in Research Studies
|
2 min read
Bill Would Remove Financial Penalties for Participating in Research Studies
|
4 min read
New Bill Would Remove Financial Penalties for Participating in Research Studies
|
3 min read